Analyst picks & changes

Matrix Pharmaceutical Inc.

(MATX)

Robert Peterson of Hanifen Imhoff initiated coverage with an "above average" rating and a 12-month price target of $24.

MATX has four

Read the full 261 word article

How to gain access

Continue reading with a
two-week free trial.